PL408251A1 - Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A - Google Patents
Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10AInfo
- Publication number
- PL408251A1 PL408251A1 PL408251A PL40825114A PL408251A1 PL 408251 A1 PL408251 A1 PL 408251A1 PL 408251 A PL408251 A PL 408251A PL 40825114 A PL40825114 A PL 40825114A PL 408251 A1 PL408251 A1 PL 408251A1
- Authority
- PL
- Poland
- Prior art keywords
- phosphodiesterase
- triazole
- inhibitors
- condensed derivatives
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Lubricants (AREA)
Abstract
Przedmiotem zgłoszenia jest związek o wzorze ogólnym (I), w którym jeden z X1 i X2 oznacza N, a drugi z X1 i X2 oznacza -C(CH3); A oznacza 5-, 6- lub 10-członowy aryl lub heteroaryl, który może być niepodstawiony lub podstawiony; B jest wybrany z grupy o wzorach B1 i B2; R oznacza H lub alkil C1-C3; jeden z Z1, Z2 i Z3 oznacza -CR1-, a pozostałe z Z1, Z2 i Z3 oznaczają -CH-; albo jeden z Z1, Z2 i Z3 oznacza N, jeden z Z1, Z2 i Z3 oznacza -CH-, i jeden z Z1, Z2 i Z3 oznacza -CR1-; R1 oznacza H, atom halogenu, CN, lub heterocykloalkil; n ma wartość 0 lub 1; oraz jego sole addycyjne z kwasami. Związek ma zastosowanie jako lek do leczenia zaburzeń i stanów psychotycznych, neurologicznych i zaburzeń funkcji poznawczych.
Priority Applications (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL408251A PL408251A1 (pl) | 2014-05-19 | 2014-05-19 | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A |
| EP15730261.3A EP3145930B1 (en) | 2014-05-19 | 2015-05-14 | Fused triazole derivatives as phosphodiesterase 10a inhibitors |
| PCT/IB2015/053549 WO2015177688A1 (en) | 2014-05-19 | 2015-05-14 | Fused triazole derivatives as phosphodiesterase 10a inhibitors |
| DK15730261.3T DK3145930T3 (en) | 2014-05-19 | 2015-05-14 | Fused triazole derivatives as phosphodiesterase 10A inhibitors |
| EA201692264A EA030330B9 (ru) | 2014-05-19 | 2015-05-14 | Конденсированные производные триазола в качестве ингибиторов фосфодиэстеразы 10a |
| SI201530382T SI3145930T1 (sl) | 2014-05-19 | 2015-05-14 | Kondenzirani triazolni derivati kot inhibitorji fosfodiesteraze 10A |
| AU2015263013A AU2015263013B2 (en) | 2014-05-19 | 2015-05-14 | Fused triazole derivatives as phosphodiesterase 10A inhibitors |
| US15/311,698 US10138245B2 (en) | 2014-05-19 | 2015-05-14 | Fused triazole derivatives as phosphodiesterase 10A inhibitors |
| PT15730261T PT3145930T (pt) | 2014-05-19 | 2015-05-14 | Derivados de triazole fundidos como inibidores da fosfodiesterase 10a |
| KR1020167035389A KR102404650B1 (ko) | 2014-05-19 | 2015-05-14 | 포스포디에스테라아제 10a 억제제로서 융합된 트리아졸 유도체 |
| HUE15730261A HUE039847T2 (hu) | 2014-05-19 | 2015-05-14 | Kondenzált triazolszármazékok foszfodiészteráz 10A inhibitorként |
| JP2016568435A JP6455947B2 (ja) | 2014-05-19 | 2015-05-14 | ホスホジエステラーゼ１０ａインヒビターとしての縮合トリアゾール誘導体 |
| MX2016015180A MX367647B (es) | 2014-05-19 | 2015-05-14 | Derivados de triazol fusionados como inhibidores de fosfodiesterasa 10a. |
| CA2946258A CA2946258C (en) | 2014-05-19 | 2015-05-14 | Fused triazole derivatives as phosphodiesterase 10a inhibitors |
| CN201580025963.XA CN106459060B (zh) | 2014-05-19 | 2015-05-14 | 作为磷酸二酯酶10a抑制剂的稠合的三唑衍生物 |
| PL15730261T PL3145930T3 (pl) | 2014-05-19 | 2015-05-14 | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A |
| ES15730261.3T ES2688084T3 (es) | 2014-05-19 | 2015-05-14 | Derivados de triazol condensados como inhibidores de fosfodiesterasa 10A |
| HRP20181027TT HRP20181027T1 (hr) | 2014-05-19 | 2018-07-05 | Derivati fuzioniranog triazola kao inhibitori fosfodiesteraze 10a |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL408251A PL408251A1 (pl) | 2014-05-19 | 2014-05-19 | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL408251A1 true PL408251A1 (pl) | 2015-11-23 |
Family
ID=53434395
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL408251A PL408251A1 (pl) | 2014-05-19 | 2014-05-19 | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A |
| PL15730261T PL3145930T3 (pl) | 2014-05-19 | 2015-05-14 | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15730261T PL3145930T3 (pl) | 2014-05-19 | 2015-05-14 | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10138245B2 (pl) |
| EP (1) | EP3145930B1 (pl) |
| JP (1) | JP6455947B2 (pl) |
| KR (1) | KR102404650B1 (pl) |
| CN (1) | CN106459060B (pl) |
| AU (1) | AU2015263013B2 (pl) |
| CA (1) | CA2946258C (pl) |
| DK (1) | DK3145930T3 (pl) |
| EA (1) | EA030330B9 (pl) |
| ES (1) | ES2688084T3 (pl) |
| HR (1) | HRP20181027T1 (pl) |
| HU (1) | HUE039847T2 (pl) |
| MX (1) | MX367647B (pl) |
| PL (2) | PL408251A1 (pl) |
| PT (1) | PT3145930T (pl) |
| SI (1) | SI3145930T1 (pl) |
| WO (1) | WO2015177688A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017007301A1 (en) * | 2015-07-06 | 2017-01-12 | Universiti Sains Malaysia | Compound and method for inhibiting sirtuin activities |
| KR102587382B1 (ko) * | 2016-04-29 | 2023-10-12 | 솔루스첨단소재 주식회사 | 유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자 |
| CN111410657B (zh) * | 2019-01-08 | 2024-05-21 | 北京鼎材科技有限公司 | 一种发光材料及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090053168A1 (en) * | 2007-07-17 | 2009-02-26 | Richard Rickles | Treatments of b-cell proliferative disorders |
| TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| US8410117B2 (en) * | 2010-03-26 | 2013-04-02 | Hoffmann-La Roche Inc. | Imidazopyrimidine derivatives |
| US8975276B2 (en) * | 2011-06-29 | 2015-03-10 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
-
2014
- 2014-05-19 PL PL408251A patent/PL408251A1/pl unknown
-
2015
- 2015-05-14 PL PL15730261T patent/PL3145930T3/pl unknown
- 2015-05-14 WO PCT/IB2015/053549 patent/WO2015177688A1/en active Application Filing
- 2015-05-14 DK DK15730261.3T patent/DK3145930T3/en active
- 2015-05-14 ES ES15730261.3T patent/ES2688084T3/es active Active
- 2015-05-14 PT PT15730261T patent/PT3145930T/pt unknown
- 2015-05-14 KR KR1020167035389A patent/KR102404650B1/ko active Active
- 2015-05-14 EP EP15730261.3A patent/EP3145930B1/en active Active
- 2015-05-14 JP JP2016568435A patent/JP6455947B2/ja active Active
- 2015-05-14 HU HUE15730261A patent/HUE039847T2/hu unknown
- 2015-05-14 MX MX2016015180A patent/MX367647B/es active IP Right Grant
- 2015-05-14 EA EA201692264A patent/EA030330B9/ru not_active IP Right Cessation
- 2015-05-14 SI SI201530382T patent/SI3145930T1/sl unknown
- 2015-05-14 CN CN201580025963.XA patent/CN106459060B/zh active Active
- 2015-05-14 US US15/311,698 patent/US10138245B2/en active Active
- 2015-05-14 AU AU2015263013A patent/AU2015263013B2/en active Active
- 2015-05-14 CA CA2946258A patent/CA2946258C/en active Active
-
2018
- 2018-07-05 HR HRP20181027TT patent/HRP20181027T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015177688A1 (en) | 2015-11-26 |
| HRP20181027T1 (hr) | 2018-08-24 |
| SI3145930T1 (sl) | 2018-10-30 |
| EA030330B1 (ru) | 2018-07-31 |
| US10138245B2 (en) | 2018-11-27 |
| CN106459060A (zh) | 2017-02-22 |
| HUE039847T2 (hu) | 2019-02-28 |
| MX367647B (es) | 2019-08-29 |
| CN106459060B (zh) | 2019-04-05 |
| CA2946258C (en) | 2023-06-06 |
| AU2015263013A1 (en) | 2016-11-17 |
| PT3145930T (pt) | 2018-10-11 |
| ES2688084T3 (es) | 2018-10-30 |
| AU2015263013B2 (en) | 2018-10-04 |
| MX2016015180A (es) | 2017-03-23 |
| EA030330B9 (ru) | 2018-09-28 |
| KR20170005860A (ko) | 2017-01-16 |
| DK3145930T3 (en) | 2018-09-24 |
| EP3145930B1 (en) | 2018-07-04 |
| KR102404650B1 (ko) | 2022-06-02 |
| EP3145930A1 (en) | 2017-03-29 |
| JP2017521364A (ja) | 2017-08-03 |
| EA201692264A1 (ru) | 2017-04-28 |
| CA2946258A1 (en) | 2015-11-26 |
| PL3145930T3 (pl) | 2018-11-30 |
| JP6455947B2 (ja) | 2019-01-23 |
| US20170114064A1 (en) | 2017-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24572B1 (es) | Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas | |
| SA515361086B1 (ar) | Fasn مركبات وتركيبات جديدة لتثبيط | |
| EA201691625A1 (ru) | Ароматические гетероциклические соединения как противовоспалительные соединения | |
| PH12017501586A1 (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| PL408251A1 (pl) | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A | |
| MA40301B1 (fr) | Composés indolecarboxamides utiles comme inhibiteurs de kinase | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MA42109A (fr) | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase | |
| EA201692418A1 (ru) | Замещенные индазольные соединения в качестве irak4 ингибиторов | |
| PH12013501197B1 (en) | Indeno-fused ring compounds | |
| EA201101297A1 (ru) | Аддитивные соли аминов, содержащих гидроксильные и/или карбоксильные группы, с производными аминоникотиновой кислоты в качестве ингибиторов dhodh | |
| MX353957B (es) | Carboxamidas heterociclicas fungicidas. | |
| SG10201900144TA (en) | Pyridone derivative having tetrahydropyranylmethyl group | |
| EA201170096A1 (ru) | Замещенные производные пиримидона | |
| MA40302B1 (fr) | Dérivés de carbazole | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| AR083180A1 (es) | Amidas de oxopiperazina-azetidina y amidas oxodiazepina-azetidina como inhibidores de monoacilglicerol lipasa | |
| MX2019013979A (es) | Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
| MX373700B (es) | Composicion acuosa novedosa. | |
| MA50418A (fr) | Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse | |
| EP2602254A4 (en) | HETEROCYCLIC CONNECTION | |
| BR112018008885A2 (pt) | composto heterocíclico condensado | |
| BR112018000925A2 (pt) | composto heterocíclico contendo nitrogênio | |
| MX377854B (es) | Derivado de 5-metil-6-fenil-4,5-dihidro-2h-piridazin-3-ona | |
| EP3802530C0 (en) | Heterocyclic compounds as class ii phosphoinositide 3-kinase inhibitors |